NeutriSci International Inc. (NU.V)
| Previous Close | 0.0600 |
| Open | 0.0700 |
| Bid | 0.0700 x 0 |
| Ask | 0.0750 x 0 |
| Day's Range | 0.0650 - 0.0700 |
| 52 Week Range | 0.0600 - 0.3500 |
| Volume | |
| Avg. Volume | 104,739 |
| Market Cap | 11.629M |
| Beta (5Y Monthly) | 2.33 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0130 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- ACCESSWIRE
NeutriSci Announces Successful Completion of R&D in Preparation for Launch of Its Functional Mushroom Product Line
VANCOUVER, BC / ACCESSWIRE / November 30, 2021 / NeutriSci International Inc. ("NeutriSci" or the "Company")(TSXV:NU)(OTCQB:NRXCF)(FSE:1N9), an innovative technology company developing products for the nutraceutical industry, is pleased to announce that is has successfully completed the R&D of a newly developed effervescent functional mushroom tablet product for online sales in Europe and North America.
- CNW Group
NeutriSci Provides Production Update and Partner Progress
NeutriSci International Inc. ("NeutriSci" or the "Company") (TSXV: NU) (OTCQB: NRXCF) (FRANKFURT: 1N9), an innovative technology company developing products, licencing, IP, and technology for B2B partnerships and the nutraceutical industry, is pleased to provide the following update.
- ACCESSWIRE
NeutriSci Receives Additional Purchase Order and Deposit from Tabletz Distribution Partner
VANCOUVER, BC / ACCESSWIRE / September 22, 2021 / NeutriSci International Inc. ("NeutriSci" or the "Company") (TSXV:NU)(OTCQB:NRXCF)(FRANKFURT:1N9), an innovative technology company developing products, licencing IP and technology for B2B partnerships and the nutraceutical industry, is pleased to announce that it has received an additional order from Tabletz LLC.
